Arcutis Biotherapeutics' second quarter reads two ways, and the difference is the whole investment case. The headline says: a small dermatology company carrying a $1.13 billion accumulated deficit earned $0.11 a share on $129.9 million of revenue, a single quarter of GAAP profit against a year-ago loss. The second reading is more useful. ZORYVE, the company's once-daily topical roflumilast franchise, generated $129.9 million of net product revenue - up 59% year over year and 23% sequentially - on its way to what looks like a clean $525–540 million full-year 2026 print, a raise of roughly $45 million at the midpoint. The quarter's operating income of $16.4 million marked the second consecutive profitable quarter. Operating cash flow turned positive - $14.9 million for the six months - and the company ended June with $238.9 million of cash and marketable securities against $108.9 million of long-term debt. The quarter carried a $2.6 million selling, general, and administrative step-up tied to the dermatology sales-force build, a $10 million research-and-development milestone for the first patient dosed in the ARQ-234 Phase 1a/1b trial, and a $5.1 million first-half interest-expense run rate - none of which masks the operating leverage. ZORYVE is no longer a launch story; it is a margin story.
The unresolved question is the one the market is pricing: is the second-quarter run rate of $130 million, which annualizes to roughly $520 million, the steady state - or is the second half of 2026 still ramping, as the implied H2 guide of $290–305 million (H1 was $235.3 million) suggests? Three things decide that. First, whether the new atopic dermatitis cream 0.05% for children 2–5 - launched October 2025 and contributing $2.9 million in Q2 alone - continues to scale into the back-to-school and back-to-pediatrician visits, the channel it was built for. Second, whether the vitiligo Phase 2 readout in Q4 2026 and the hidradenitis suppurativa data in Q1 2027 produce a third and fourth growth lane out of the same ZORYVE foam. Third, whether the recently terminated Kowa primary-care partnership - the company is now back selling direct with a targeted pediatric-and-primary-care team in the field by the end of August - produces or disrupts demand. The two-sentence summary: ZORYVE grew 59% and earned money for the second quarter in a row; the rest of 2026 is execution on a base that, on the current trajectory, the market is treating as durable. The stock at $25.83 sits roughly 19% off its December 2025 high of $31.77 and 71% off its August 2025 low of $15.10 - the price is on the question, not the answer.